Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Study Identifier:
ALXN2050-HV-110
ClinicalTrials.gov Identifier:
NCT05202145
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN2050
  • Drug: Cyclosporine
  • Drug: Tacrolimus
  • Drug: MMF
Date
Jan 2022 - Mar 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN2050
  • Drug: Cyclosporine
  • Drug: Tacrolimus
  • Drug: MMF
Date
Jan 2022 - Mar 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).

Trial Locations

Location
Status
Location
Clinical Study Site
Tempe, Arizona, United States, 85283
Status
N/A